Trade names Travatan MedlinePlus a602027 Legal status US: ℞-only Molar mass 500.548 g/mol Duration of action ≥ 24 hours DrugBank DB00287 | AHFS/Drugs.com Monograph Routes of
administration Topical (eye drops) CAS ID 157283-68-6 Onset of action 2 hours ATC code S01EE04 (WHO) | |
 | ||
Pregnancy
category US: C (Risk not ruled out) Biological half-life 1.5 hours (in aqueous fluid); 45 minutes (terminal) | ||
Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a synthetic prostaglandin analog (or more specifically, an analog of prostaglandin F2α) that works by increasing the outflow of aqueous fluid from the eyes. It is also known by the brand names of Travatan and Travatan Z, manufactured by Alcon.
Contents
Side effects
Possible side effects are:
Mechanism of action
Like other analogs of prostaglandin F2α such as tafluprost and latanoprost, travoprost is an ester prodrug of the free acid, which acts as an agonist at the prostaglandin F receptor, increasing outflow of aqueous fluid from the eye and thus lowering intraocular pressure.
Pharmacokinetics
Travoprost is absorbed through the cornea, where it is hydrolysed to the free travoprost acid. Highest concentrations of the acid in the eye are reached one to two hours after application, and its half-life in the aqueous fluid is 1.5 hours. Once it reaches the bloodstream, it is quickly metabolised, so that concentrations in the system do not exceed 25 pg/ml (compared to 20 ng/ml in the eye, which is higher by nearly a factor of 1000).
Metabolites are formed by beta oxidation of the acidic chain (compare Tafluprost#Pharmacokinetics), oxidation of the OH-group in the other side chain, and reduction of the double bond next to this OH-group. Travoprost acid and its metabolites are mainly excreted via the kidney with a terminal half-life of 45 minutes.